Holen Sie sich die Stockscreener-App
12.07
5.51%
0.63
Handel nachbörslich:
12.07
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Enanta Pharmaceuticals (ENTA) Rises 3.4% as Biotech Eyes Key Resistance at $12.5Dividend Growth Stocks - newsline.com
Understanding Momentum Shifts in (ENTA) - Stock Traders Daily
AP Chemistry students tour Enanta Pharmaceuticals labs for hands-on drug discovery experience - Traders Union
Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Enanta Pharmaceuticals (ENTA) Holds Near Support as Trading Volume Remains SubduedOverbought Signal Alerts - newsline.com
Avoiding Lag: Real-Time Signals in (ENTA) Movement - Stock Traders Daily
Enanta Pharmaceuticals Advances RSV Treatment and Immunology Pip - GuruFocus
Enanta Pharmaceuticals Advances RSV Treatment and Immunology Pipeline - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2026 - BioSpace
Enanta Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 28, 2026, at 11:00 AM GMT - geneonline.com
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
Enanta Pharmaceuticals (ENTA) Edges Higher, Testing Resistance Near $14.65Calendar Spread Trade - The Legal Advocate
Discipline and Rules-Based Execution in ENTA Response - Stock Traders Daily
Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews
Enanta Pharmaceuticals (ENTA) Delivers Q1 2026 Beat — EPS $-0.45 vs $-0.50 ExpectedEPS Consistency Score - newsline.com
TradingKey - TradingKey
Enanta Pharmaceuticals Q2 2026 Financial Results and Management Discussion – 10-Q Report Highlights - Minichart
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary - TradingView
Enanta Pharmaceuticals (NASDAQ: ENTA) trims losses on higher HCV royalties and lower R&D - Stock Titan
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta (ENTA) Reports Strong Q2 Revenue and Progress in Clinical Trials - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q2 FY26 Beat? - GuruFocus
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus - ChartMill
ENANTA PHARMACEUTICALS ($ENTA) Releases Q2 2026 Earnings - Quiver Quantitative
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Weekly Voice
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - marketscreener.com
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
MSN Money - MSN
Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Behavioral Patterns of ENTA and Institutional Flows - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Progr - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - BioSpace
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - MSN
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ENTA Price Today: Enanta Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ENTA (Enanta Pharmaceuticals Inc.) posts 49 percent narrower Q1 2026 loss than expected, shares fall 3.37 percent on slight revenue decline.Management Guidance - Xã Thanh Hà
How (ENTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):